- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01842386
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases
Background:
- Healthy people have white blood cells that protect them against bacteria, viruses, and fungi. However, some people have diseases which cause the body to make white blood cells that do not work properly. These white blood cells can attack the body s own proteins. These types of diseases are called anti-cytokine autoantibody-associated diseases. They can cause severe illnesses and even death. They are also difficult to treat with standard drugs.
- Rituximab is a drug used to treat rheumatoid arthritis. It attacks white blood cells that do not work properly. Currently, it is not approved for treating anti-cytokine autoantibody-associated diseases. However, researchers think that it may be able to help treat people with these immune diseases.
Objectives:
- To see if rituximab is a safe and effective treatment for anti-cytokine autoantibody-associated diseases.
Eligibility:
- Individuals at least 18 years of age who have anti-cytokine autoantibody-associated diseases.
- Participants must also be enrolled in a related immune disorder study at the National Institutes of Health.
Design:
- The study will last 24 months. Participants will take rituximab for 6 months and have follow-up visits for the remaining 18 months.
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Other samples will be collected as needed if participants currently have an infection.
- Participants will enter the hospital for 1 week at the start of treatment. They will have four doses of rituximab given 2 days apart. This first treatment will be monitored with frequent blood tests.
- Over the next 6 months, participants will have four more doses of rituximab given about 1 month apart. Treatment will be monitored with frequent blood tests and sample collections as needed.
- There will be four follow-up study visits at 3, 6, 12, and 18 months after the last dose of rituximab.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
- INCLUSION CRITERIA:
Subjects (greater than or equal to 18 years of age) are eligible if they meet the following criteria:
- Currently enrolled in one of the following protocols: 95-I-0066, 07-I-0033, 01-I-0202, or 93-I-0119.
Presence of anticytokine autoantibodies in serum or plasma, along with the anticipated clinical consequences of the identified anticytokine autoantibody including, but not limited to:
- Anti-IFN- >= autoantibodies and disseminated NTM.
- Anti-IL-17 autoantibodies and CMC.
- Anti-GM-CSF autoantibodies and PAP or cryptococcosis.
Progression of anticytokine autoantibody-associated diseases despite conventional therapy, including, but not limited to:
- Antimycobacterials for disseminated NTM.
- Antifungals for mucocutaneous candidiasis or cryptococcosis.
- Subcutaneous or inhaled GM-CSF and/or whole lung lavage for PAP.
- For ongoing autoantibody-associated infection, stable, optimized antibiotic regimen for at least 1 month prior to initiation of rituximab and ability to continue these antibiotics throughout treatment with rituximab.
- Willingness to comply with study medication, visits, and procedures, as deemed necessary by the study investigator.
- Willingness to have samples stored for future research and genetic testing.
- Willingness to be hospitalized for the inpatient visits (initial doese on day 1 and day 15 will occur in the inpatient unit.
Negative serum pregnancy test result for women of childbearing potential.
- Women of childbearing potential and men are eligible if they agree to postpone conception for 18 months following rituximab therapy. They must agree to use 2 adequate methods of contraception, such as:
- Hormonal contraception.
- Male or female condoms with or without a spermicide, diaphragm or cervical cap with a spermicide, or intrauterine device.
- Sterilization of either partner.
EXCLUSION CRITERIA:
Subjects who meet the following criteria are not eligible to enter the study:
- HIV seropositivity.
- Active underlying malignancy, except thymoma and basal and squamous cell carcinoma.
Immunomodulatory or immunosuppressive therapy, including:
- Corticosteroids at a dose equivalent to greater than or equal to 15 mg of prednisone/day at any time during the month immediately prior to enrollment.
- History of using biologic agents or any other systemic immune-suppressive or immunomodulatory agents within the past year.
- Use of another investigational study agent within 8 weeks of enrollment.
- Known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or any component of the study medication.
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
- Evidence of significant uncontrolled concomitant diseases, such as cardiovascular disease, or nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders.
- Diagnosis of an unrelated underlying immunodeficiency.
- Hepatitis B (subjects with hepatitis C are eligible to enter the study).
- Live vaccines within 1 month prior to receiving the study drug.
- Unsuitable participation as judged by the principal investigator.
- History of cancer, including solid tumors and hematologic malignancies (except basal cell or squamous cell carcinoma of the skin that have been excised and cured and thymoma).
- History of alcohol, drug, or chemical abuse within 6 months prior to screening.
- Poor peripheral venous access.
- Intolerance or contraindications to oral or IV corticosteroids.
Screening laboratory values:
- Serum creatinine >1.4 mg/dL for women and >1.6 mg/dL for men.
- Platelet count <100,000/ L.
- Absolute neutrophil count <1500 cells/ L.
- IgG <5.65 times 10(-2) mg/dL or IgM <0.55 times 10(-2) mg/dL.
- Breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rituximab
Adults (=18 years of age) with anticytokine autoantibodyassociated diseases who are refractory to conventional treatment and who test negative for the human immunodeficiency virus (HIV)
|
Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42.
Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
safe and tolerable administration of rituximab in subjects with anticytokine autoantibody-associated diseases who are refractory to conventional treatment
Time Frame: at study end
|
safe and tolerable administration of rituximab in subjects with anticytokine autoantibody-associated diseases who are refractory to conventional treatment
|
at study end
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christa S Zerbe, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Bacterial Infections and Mycoses
- Skin Diseases, Infectious
- Mycoses
- Dermatomycoses
- Chronic Disease
- Candidiasis
- Pulmonary Alveolar Proteinosis
- Candidiasis, Chronic Mucocutaneous
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- 130082
- 13-I-0082
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Alveolar Proteinosis (PAP)
-
Assistance Publique - Hôpitaux de ParisRecruitingGenetic Mutation | Pulmonary Alveolar Proteinosis (PAP) | MARSFrance
-
Guangzhou Institute of Respiratory DiseaseActive, not recruitingPulmonary Alveolar Proteinosis(PAP)China
-
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd...The First Affiliated Hospital of Guangzhou Medical UniversityNot yet recruitingAutoimmune Pulmonary Alveolar Proteinosis
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI); University of South FloridaRecruiting
-
Children's Hospital Medical Center, CincinnatiGenzyme, a Sanofi Company; Virginia Commonwealth UniversityCompletedHereditary Pulmonary Alveolar ProteinosisUnited States
-
Niigata University Medical & Dental HospitalCompletedPulmonary Alveolar Proteinosis, AutoimmuneJapan
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI); Rare Diseases Clinical Research...CompletedAutoimmune Pulmonary Alveolar ProteinosisUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedAutoimmune Pulmonary Alveolar ProteinosisUnited States
-
IRCCS Policlinico S. MatteoAgenzia Italiana del FarmacoCompleted
-
Savara Inc.CompletedAutoimmune Pulmonary Alveolar ProteinosisNetherlands, Denmark, France, Germany, Greece, Israel, Italy, Russian Federation, Turkey, United Kingdom
Clinical Trials on Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States